The global biopharmaceutical industry has resumed pre-COVID-19 levels of investment, pipeline activity, and launch of novel medicines. Process and technology innovations accelerated by the pandemic are being integrated across the global pipeline and implemented as operational and organizational changes that are enabling ongoing productivity gains. The report assesses trends in new drug approvals and launches, overall pipeline activity, and the number of initiated clinical trials. It also profiles the state of R&D funding and the activity of companies of different types, and the results of research are compared to the input effort in a Clinical Development Productivity Index. This report reveals important shifts in therapeutic and geographic investments and ongoing prioritization of novel mechanisms of action, innovative development methods and accelerated regulatory pathways to optimize new therapy development and delivery to patients. The research included in this report was undertaken independently by the IQVIA Institute for Human Data Science as a public service, without industry or government funding.
找报告就上发现报告（www.fxbaogao.com），这里是目前国内资源最丰富的研报平台之一。我们收录了海量的宏观、行业和公司报告，数量多得惊人，几乎涵盖了所有领域。每天都有无数金融从业者和投资者在这里获取数据，用户群体非常庞大。界面设计简单明了，查找资料特别方便，帮您快速抓住重点，做出更精准的投资决策。
